The efficacy and safety of wedge resection for peripheral stage IA lung adenocarcinoma: a real-world study based on a single center

被引:3
|
作者
Bian, Dongliang [1 ]
Xiong, Yicheng [1 ]
Jin, Kaiqi [1 ]
Zhu, Yuming [1 ]
Yu, Huansha [2 ]
Dai, Jie [1 ]
Jiang, Gening [1 ]
机构
[1] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Thorac Surg, Shanghai, Peoples R China
[2] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Anim Expt Ctr, Shanghai, Peoples R China
基金
中国国家自然科学基金; 国家重点研发计划;
关键词
Lung adenocarcinoma stage IA; wedge resection; recurrence; SECTION COMPUTED-TOMOGRAPHY; LIMITED RESECTION; SUBLOBAR RESECTION; SURVIVAL OUTCOMES; CANCER; LOBECTOMY; IMPACT; CLASSIFICATION;
D O I
10.21037/jtd-22-1010
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: The effectiveness of segmentectomy for stage IA lung adenocarcinoma (IA-LUAD) has been well-documented. However, the efficacy and safety of wedge resection for peripheral IA-LUAD remains controversial. This study evaluated the feasibility of wedge resection in patients with peripheral IA-LUAD. Methods: Patients with peripheral IA- LUAD who underwent wedge resection by video- assisted thoracoscopic surgery (VATS) at Shanghai Pulmonary Hospital were reviewed. Cox proportional hazards modeling was performed to identify predictors of recurrence. Receiver operating characteristic (ROC) curve analysis was used to calculate the optimal cutoffs of identified predictors. Results: A total of 186 patients (female/male, 115/ 71; mean age, 59.9 years) were included. Mean maximum dimension of consolidation component (MCD) was 5.6 mm, consolidation-to-tumor ratio (CTR) was 37%, and mean computed tomography value of tumor (CTVt) was -285.4 HU. With a median follow-up of 67 months (interquartile range, 52-72 months), the 5-year recurrence rate was 4.84%. Ten patients occurred recurrence postoperatively. No recurrence was observed adjacent to the surgical margin. Increasing MCD, CTR, and CTVt were associated with a higher risk of recurrence, with corresponding hazard ratios (HRs) of 1.212 [95% confidence interval (CI): 1.120-1.311], 1.054 (95% CI: 1.018-1.092), and 1.012 (95% CI: 1.004-1.019) with optimal cutoffs for predicting recurrence of 10 mm, 60%, and -220 HU, respectively. When a tumor had characteristics under these respective cutoffs, no recurrence was observed. Conclusions: Wedge resection can be considered to be a safe and efficacious management strategy for patients with peripheral IA-LUAD, especially for MCD less than 10 mm, CTR less than 60% and CTVt less than -220 HU.
引用
收藏
页码:54 / 64
页数:11
相关论文
共 50 条
  • [21] EFFICACY AND SAFETY OF PCSK9 MONOCLONAL ANTIBODIES IN OLDER ADULTS: A REAL-WORLD SINGLE CENTER COHORT STUDY
    Steward, Kim
    Mulder, Janneke W. C. M.
    Galema-Boers, Annette M. H.
    Van Lennep, Jeanine Roeters
    ATHEROSCLEROSIS, 2024, 395
  • [22] Appropriate Sublobar Resection Choice for Ground Glass Opacity-Dominant Clinical Stage IA Lung Adenocarcinoma Wedge Resection or Segmentectomy
    Tsutani, Yasuhiro
    Miyata, Yoshihiro
    Nakayama, Haruhiko
    Okumura, Sakae
    Adachi, Shuji
    Yoshimura, Masahiro
    Okada, Morihito
    CHEST, 2014, 145 (01) : 66 - 71
  • [23] Real-World Efficacy and Safety of Sintilimab-Based Regimens against Advanced Esophageal Cancer: A Single-Center Retrospective Observational Study
    Wang, Chenyu
    Jin, Linzhi
    Cheng, Xinyu
    Ren, Runchuan
    Zheng, Anping
    Hao, Anlin
    Wang, Nengchao
    Zhang, Jinwen
    Zhou, Fuyou
    Zhang, Yaowen
    BIOMED RESEARCH INTERNATIONAL, 2022, 2022
  • [24] Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: A single-center experience
    Ohata, Chika
    Ohyama, Bungo
    Katayama, Eri
    Nakama, Takekuni
    JOURNAL OF DERMATOLOGY, 2020, 47 (04): : 405 - 408
  • [25] Efficacy and safety of adjuvant chemotherapy in lung cancer: Real-world evidence
    Roitberg, F. S. R.
    Neffa, M. F. B. V.
    Bonadio, R. R. C. C.
    Harada, G.
    Mendoza, E. Z.
    Mak, M. P.
    Takahashi, T. K.
    Martins, R. E.
    Mesquita, C.
    Santini, F. C.
    de Araujo, P. H. X. N.
    Lauricella, L. L.
    Prado, G. F.
    Takagaki, T. Y.
    de Mello, E. S.
    Gabrielli, F.
    de Andrade Carvalho, H. D. A.
    Terra, R. M.
    de Castro, G., Jr.
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] Efficacy and Safety of Telitacicept in IgA Nephropathy: A Real-World Study
    Dong Lingqiu
    Qin Wei
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [27] Efficacy and safety of telitacicept in IgA nephropathy: a real-world study
    Dong, Lingqiu
    Qin, Wei
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [28] Efficacy and Safety of Anlotinib in the Treatment of Small Cell Lung Cancer: A Real-World Observation Study
    Yuan, Jing
    Cheng, Feng
    Xiao, Guodong
    Wang, Xiaofeng
    Fan, Huijie
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [29] Efficacy and safety of telitacicept in IgA nephropathy: a real-world study
    Dong, Lingqiu
    Qin, Wei
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I712 - I713
  • [30] Efficacy and safety of telitacicept in IgA nephropathy: a real-world study
    Dong, Lingqiu
    Yang, Dandan
    Qin, Aiya
    Wang, Siqing
    Tang, Yi
    Tan, Jiaxing
    Qin, Wei
    RENAL FAILURE, 2025, 47 (01)